SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025, reflecting sustained momentum for its SSi Mantra surgical robotic platform.
The revenue surge was driven by a 30.4% increase in SSi Mantra installations during the quarter, with 30 systems deployed. The installed base now stands at 224 systems across 12 countries, and cumulative surgeries have reached 12,272. This expansion underscores the growing adoption of the SSi Mantra system in diverse healthcare markets.
Gross profit for the second quarter rose 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit increased 77.5% to $12.4 million, with an improved gross margin compared to the prior year. The margin dip in Q2 may reflect increased investments in scaling operations and supporting global installations.
Looking ahead, regulatory milestones could serve as significant catalysts for SS Innovations. The company is targeting FDA clearance for the SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to two of the world's largest medical device markets, potentially accelerating growth.
The company's telesurgery achievements are also extending the clinical profile of SSi Mantra, showcasing its capabilities beyond traditional operating rooms. Telesurgery allows surgeons to operate remotely, which could expand access to specialized surgical care in underserved regions. While system installations remain the primary commercial growth driver, these technological advancements enhance the platform's value proposition.
The strong financial performance and expanding global footprint position SS Innovations as a key player in the surgical robotics industry. The company's growth comes at a time when demand for minimally invasive surgical options is rising, and robotic-assisted procedures are becoming more prevalent. The successful integration of SSi Mantra into multiple countries suggests that the platform is competitive with established players.
Investors and industry observers will be watching for continued progress in regulatory submissions and further adoption of the technology. The company's ability to maintain its growth trajectory while navigating regulatory hurdles will be critical. As the installed base grows, recurring revenue from service and maintenance contracts could provide additional stability.
For more detailed financial information, the company's newsroom offers updates at https://nnw.fm/SSII. The latest news and updates relating to SSII are available at https://nnw.fm/zxrT1.
